|
課程名稱 |
生物科技管理與產業分析
Management and Analysis in the Biotechnology Industry |
|
開課學期 |
106-2 |
|
授課對象 |
生物資源暨農學院 生物科技研究所 |
|
授課教師 |
孫智麗 |
|
課號 |
Biot7013 |
|
課程識別碼 |
642 M0140 |
|
班次 |
|
|
學分 |
2.0 |
|
全/半年 |
半年 |
|
必/選修 |
選修 |
|
上課時間 |
星期五8,9(15:30~17:20) |
|
上課地點 |
生技館214 |
|
備註 |
限碩士班以上
總人數上限：20人 |
|
|
|
|
課程簡介影片 |
|
|
核心能力關聯 |
核心能力與課程規劃關聯圖 |
|
課程大綱
|
|
為確保您我的權利,請尊重智慧財產權及不得非法影印
|
|
課程概述 |
生技產業以生物技術為主軸，如何判斷一個新創技術或產品的價值則是另一個複雜的課題 (新技術或產品上市的產值是五千萬元？五億元？還是十億元？)。判斷無形資產技術的價值(生物技術鑑價或評價)，除技術本身外，尚需結合與技術相關之 1.產業分析 2.市場分析 3.財經分析 4.商業模式分析 5.研發管理 6.專利佈局等資訊。
生物技術相關課程眾多，對於生技鑑價(評價)的課題著墨卻不多。本課程為彌補此一不足，使學生對於生物技術鑑價(評價)有完整且深入的了解，課程設計分為兩部分：一為教師授課、二為文獻選讀。第一部分將從臺灣及全球生物技術產業分析開始，並進一步探討臺灣生技產業的調查、價值鏈/供應鏈等說明，最後介紹技術評價原理、方法及案例分析。而第二部分將透過文獻選讀，深入探討近年全球在生物技術產業的技術鑑價(評價)、專利佈局、創業投資等議題，使學生對生技產業有更深入全面的了解。歡迎具生物科技相關背景、或對生技產業分析與科技管理及技術評價有興趣的同學選修。 |
|
課程目標 |
課程核心能力發展目標：
1. 創新思考及問題解決能力
2. 團隊溝通與合作與能力
3. 領導與跨領域整合能力
4. 國際觀
5. 終身自我學習
課程內容涵蓋以下主題：
1. Industry Analysis
2. Market Analysis
3. Financing
4. Business Development
5. R&D Management
6. Technology Licensing
7. Technology Valuation |
|
課程要求 |
學期成績評量方式：期中課堂表現（口頭簡報、學習態度與成效等）占50%；期末報告（中文重點摘譯彙整報告）占50%。修課同學在學期末要從本學期課表以下七個主題中選擇其中一個主題的至少兩篇papers進行中文重點摘譯彙整報告/word檔（12號字、含圖表約3,000字、專有名詞/公司名/技術名/藥名/人名不要翻成中文、檔案不超過1M），於6月26日23:30前Email給教師（Email: juliesun@ntu.edu.tw）。 |
|
預期每週課後學習時數 |
|
|
Office Hours |
|
|
指定閱讀 |
|
|
參考書目 |
1.Lessons from 60 years of pharmaceutical innovation, Nature Reviews Drug Discovery 8: p959, 2009.
2.The importance of new companies for drug discovery: origins of a decade of new drugs, Nature Reviews Drug Discovery 9: p867, 2010.
3.Strategic groups in the biopharmaceutical industry: implications for performance, Drug Discovery Today 14: p726, 2009.
4.Value networks identify innovation in 21st century pharmaceutical research, Drug Discovery Today 14: p68, 2009.
5.How many patents does a biopharmaceutical company need? Nature Biotechnology 26: p763, 2008.
6.What’s fueling the biotech engine 2012-2013, Nature Biotechnology 32: p32, 2014.
7.A decade of change, Nature Reviews Drug Discovery 11: p17, 2012.
8.2015 FDA drug approvals, Nature Reviews Drug Discovery 15: p73, 2016.
9.Medicare formulary coverage for top – selling biologics, Nature Biotechnology 27: p1082, 2009.
10.The view beyond venture capital, Nature Biotechnology 32: p15, 2014.
11.Biotech's wellspring-the health of the private sector in 2014, Nature Biotechnology 33: p470, 2015.
12.Portfolio analysis and R&D decision making, Nature Reviews Drug Discovery 8: p189, 2009.
13.Pharmaceutical R&D: the road to positive returns, Nature Reviews Drug Discovery 8: p609, 2009.
14.The ‘big pharma’ dilemma: develop new drugs or promote existing ones? Nature Reviews Drug Discovery 8: p533, 2009.
15.Does R&D pay? Drug Discovery Today 15:230, 2010.
16.Commercialization strategies of young biotechnology firms, Research Policy 37: p1765, 2008.
17.Biotech acquisitions by big pharma: why and what is next, Drug Discovery Today 14: p818, 2009.
18.Six secrets to success—how to build a sustainable biotech business, Nature Biotechnology 27: p595, 2009.
19.The seven deadly sins of business development, Nature Biotechnology 26: p375, 2008.
20.Making the leap into entrepreneurship, Nature Biotechnology 28: p11, 2010.
21.Coming to terms: Before taking other people’s money to finance your venture, it pays to fully educate yourself, Nature Biotechnology 28: p120, 2010.
22.How were new medicines discovered? Nature Reviews Drug Discovery 10, p507, 2011.
23.Assessing the translatability of drug projects: what needs to be scored to predict success? Nature Reviews Drug Discovery 8: p541, 2009.
24.The case for entrepreneurship in R&D in the pharmaceutical industry, Nature Reviews Drug Discovery 9:p683, 2010.
25.Drug discovery: are productivity metrics inhibiting motivation and creativity? Drug Discovery Today 13: p997, 2008.
26.Managing freedom: Managing researchers as if they were warriors, Drug Discovery Today 13: p555, 2008.
27.Project management of life-science research projects: project characteristics, challenges and training needs, Drug Discovery Today 16: p93, 2011.
28.Leveraging your biotech intellectual property, Nature Biotechnology 26: p607, 2008.
29.The economics of licensing contracts, Nature Biotechnology 26: p855, 2008.
30.Licensing: pros and cons for biotech, Drug Discovery Today 14: p227, 2009.
31.Reaching across the table, Nature Biotechnology 30: p485, 2012.
32.Disclosing discoveries, Nature Biotechnology 28: p9, 2010.
33.Determining the value of drug development candidates and technology platforms, Journal of Commercial Biotechnology 11(2), p.155, 2005.
34.How to improve R&D productivity: the pharmaceutical industry’s grand challenge, Nature Reviews Drug Discovery 9: p203, 2010.
35.The Cost of Biopharmaceutical R&D: Is Biotech Different? Managerial and Decision Economics 28: p469, 2007.
36.Putting a price on biotechnology, Nature Biotechnology 19: p5, 2001.
37.Clinical development success rates for investigational drugs, Nature Biotechnology 32: p40, 2014. |
|
評量方式
(僅供參考) |
|
|